Gerty Schreibelt is an immunologist at the department of Tumor Immunology of the Radboud Institute for Molecular Life Sciences. Her research primarily focuses on human natural circulating DC subsets, to understand the functional properties of these dendritic cells and to establish their value for clinical vaccination of cancer. She is highly involved in clinical trials with dendritic cell vaccination of melanoma, prostate cancer and colon carcinoma as well as prophylactic vaccination of Lynch syndrome carriers, to translate findings from preclinical studies into new immunological approaches for treatment of cancer patients. Research interests include antigen uptake, -processing and –presentation by natural dendritic cell subsets and Toll-like receptor mediated dendritic cell maturation, in particular with GMP-grade products for direct application in dendritic cell-based immunotherapy of cancer patients.
Gerty Schreibelt obtained her Masters degree in Biology from the University of Groningen in 2002 and her PhD from the VU University in Amsterdam in 2007. Her thesis focused on the role of reactive oxygen species and oxidative stress in the formation of inflammatory multiple sclerosis lesions. During her PhD, she was a visiting scientist at the Leibniz-Institut für Molekulare Pharmakologie in Berlin, Germany. After obtaining her PhD in 2007, she joined the department of Tumor Immunology in Nijmegen, where she studies the use of dendritic cells as anti-cancer vaccines.Gerty’s research mainly focusses on natural circulating dendritic cell subsets and their application in immunotherapy of cancer. In a recent clinical study, she showed that immunotherapy with naturally circulating dendritic cells can induce potent anti-tumor immune responses and objective clinical responses in advanced melanoma patients. A phase III randomized placebo-controlled trial to prove clinical efficacy of dendritic cell-based immunotherapy is currently ongoing in stage IIIB and IIIC melanoma patients. Gerty is a member of the Dutch-Flemish workgroup on Advanced Therapy Medicinal Products.
Key words: Tumor immunology, Cancer Immunotherapy, dendritic cell vaccines, naturally circulating dendritic cell subsets
- Vaccination with tumor antigen-loaded natural circulating dendritic cell subsets can induce functional anti-tumor immune responses and objective clinical responses in advanced cancer patients (Cancer Research 2013; Clinical Cancer Research 2016).
- Plasmacytoid and myeloid blood dendritic cells can take up and cross-present tumor antigens to CD8+ T cells (Blood 2013).
- The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-) presentation by human blood BDCA3+ myeloid dendritic cells (Blood 2012).
- Prophylactic vaccines contain toll-like receptor ligands and can be used as clinical grade maturation factor for dendritic cells for immunotherapy of cancer (Blood 2010; Cancer Immunol Immunother 2016).
- Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EHJG, Duiveman-de Boer T, van de Rakt MWMM, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MAM, van Oorschot TGM, Tel J, Winkels G, Petry K, Blokx WAM, van Rossum MM, Welzen MEB, Mus RDM, Croockewit AJ,Koornstra RHT, Jacobs JFM, Kelderman S, Blank CU,Gerritsen WR, Punt CJA, Figdor CG, de Vries IJM, Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res, 2016. 22(9): 2155-2166.
- Bol KF, Aarntzen EHJG, Pots JM, Olde Nordkamp MAM, van de Rakt MWMM, Scharenborg NM, de Boer AJ, van Oorschot TGM, Croockewit S, Blokx W, Oyen WJG, Boerman OC, Mus R, van Rossum M, van der Graaf CAA, Punt CJA, Adema GJ, Figdor CG, de Vries IJM, Schreibelt G,Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother, 2016. 65(3): 327-339.
- Tel J*, Schreibelt G*, Sittig SP, Mathan TSM, Buschow SI, Cruz LJ, Lambeck AJA, Figdor CG, de Vries IJM, Human circulating plasmacytoid dendritic cells efficiently cross-present exogenous antigens to CD8+ T cells, despite lower antigen uptake than myeloid dendritic cell subsets.Blood, 2013. 121(3): 459-467.
- Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJM, The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012. 119(10): 2284-92.
- Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJM, Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010. 116(4): 564-74.